About the Journal

Download [This article belongs to Volume - 140, Issue - 05]

Abstract : Since first recognized in Wuhan, China, COVID-19 infection has continued to grow worldwide. By the end of September 2020, more than one million cases had died from the disease. This study aims to assess the mortality in hospitalized patients with severe COVID-19 and explore the demographical, clinical, and biochemical association to mortality. A retrospective, observational study, performed in COVID-19 Center in Misan province, Iraq, on in-patients aged 18 years and older, with a confirmed diagnosis of COVID-19 by RT-PCR on a nasopharyngeal swab. Out of 202 patients in the study, males represent 63.3%. Demographical, clinical, and blood tests results were extracted from the hospital records and compared between survivors and non-survivors. Of 202 patients in our study, 42 patients died, and 160 patients were discharged home. The median age of the patients was 57 years (±14.5 years). About 77.4% of them had at least one comorbid condition, with hypertension being most common, present in 52.4%, diabetes 45.5%, ischemic heart disease 17.8%, chronic obstructive pulmonary disease 6.9%, and heart failure in 5.9%. By frequency, the most common symptom are cough, fever, fatigue, headache, nausea, diarrhea, and hiccup. There was a significant association related to mortality from COVID-19 found with age, duration of symptoms before admission, oxygen saturation on entry, white blood cell count, platelets, serum ferritin, lactate dehydrogenase, and D-dimer level. Hospitalized patients with severe COVID-19 had a death rate of 20.8 percent. In patients with severe illness, several demographical, clinical, and inflammatory variables show a substantial link to in-hospital mortality. Using these results to forecast illness severity might allow us to focus our limited efforts on individuals who are at a high risk of death.

Copyright © 2020 All rights reserved | Bulletin of National Institute of Health Sciences